SE1 Chart, page-8

The good news with Sensera is the market cap is now insanely cheap ($36m @ 22c) and in a few years time the revenue will be greater than the current market cap...... More money has been spent on the development of Nanotron over the years than the current market cap and dont forget about the fab and the significance of the $11b medtech client Abiomed who's products are changing the world for the better and just how big a part sensera plays in their supply chain.... Sensera would be worth far more to Abiomed than the current measly market cap thats for sure....

Its all about risk to reward and SE1 would have to be one of the most compelling buys on the ASX right now!